Raav/aβ
Raav/aβ has been studied in 1 paper since 2016: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Aug 29, 2016: “An Oral Aβ Vaccine Using a Recombinant Adeno-Associated Virus Vector in Aged Monkeys: Reduction in Plaque Amyloid and Increase in Aβ Oligomers”.
1 paper studies it3 findingsUpdated
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- Animals1
What did studies of raav/aβ find?
3Studies of raav/aβ measured 3 outcomes: inflammation, Aβ oligomers and amyloid plaque burden.
Inflammation
no changein non-human primates1
1 study
Inflammation
no changein non-human primates1
Raav/aβ showed no clear effect on inflammation in non-human primates (aged non-human primates).
“without inflammatory or hemorrhagic changes in the brain”
Animalsaged non-human primatesenteric-dissolving coated capsulesbrain
Journal of Alzheimer's disease : JAD
Aβ oligomers
upin non-human primates1
1 study
Aβ oligomers
upin non-human primates1
Raav/aβ increases Aβ oligomers in non-human primates (aged non-human primates).
“soluble Aβ and some Aβ oligomers were increased in rAAV-treated monkey brains”
Animalsaged non-human primatesenteric-dissolving coated capsulesbrain
Journal of Alzheimer's disease : JAD
Amyloid plaque burden
downin non-human primates1
1 study
Amyloid plaque burden
downin non-human primates1
Raav/aβ decreases amyloid plaque burden in non-human primates (aged non-human primates).
“Pathological examinations of the brain showed significant reduction of the amyloid plaque burden and intracellular Aβ”
Animalsaged non-human primatesenteric-dissolving coated capsulesbrain
Journal of Alzheimer's disease : JAD